Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: SGLT2 inhibitors


The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

May 26th 2022

The primary objective of this article is to examine the clinical benefit, safety, and tolerability of the four SGLT2 inhibitors approved by the US FDA. SGLT2 inhibitors increase urinary glucose excretion via inhibiting SGLT2 to decrease renal reabsorption of filtered glucose and reduce the renal threshold for glucose (Cardiovascular Diabetology)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin

May 25th 2022

As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin (Annals of Internal Medicine)

Categories: Medication, News
Tags: metformin, SGLT2 inhibitors

Categories: Medication
Tags: metformin, SGLT2 inhibitors

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus

May 18th 2022

The risks for subsequent development of HF, MI, AP, stroke, and AF were comparable between individual SGLT2 inhibitors. This is the first study comparing the wide-range cardiovascular outcomes of patients with DM treated with individual SGLT2 inhibitors using large-scale real-world data (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: SGLT2 inhibitors

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

May 16th 2022

Type 2 diabetic AMI patients receiving SGLT2-I exhibited significantly reduced inflammatory response and smaller infarct size compared to those receiving other OAD agents independently of glucose-metabolic control (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: AMI, hyperglycemia, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: AMI, hyperglycemia, SGLT2 inhibitors

Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study

May 14th 2022

Use of SGLT2 inhibitors, as compared with GLP-1 receptor agonists, was not associated with a statistically significant increase in risk of bladder cancer (Diabetes Care)

Categories: Medication, News
Tags: bladder, cancer, renal, SGLT2 inhibitors

Categories: Medication
Tags: bladder, cancer, renal, SGLT2 inhibitors

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER

April 27th 2022

Global use of glucose-lowering medications with established cardiovascular benefits has increased over time but remains suboptimal, particularly in sub-groups most likely to benefit. Substantial country-level variability exists independent of patient factors, suggesting structural barriers may limit more widespread use of these medications (BMC Endocrine Disorders)

Categories: Medication, News
Tags: DISCOVER, GLP-1 receptor agonists, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: DISCOVER, GLP-1 receptor agonists, SGLT2 inhibitors, Type 2 Diabetes

Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials

April 11th 2022

SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk and/or with CKD, without increasing the risk of hypokalemia

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: CKD, hyperkalemia, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication, Nephropathy
Tags: CKD, hyperkalemia, SGLT2 inhibitors, Type 2 Diabetes

Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes

April 10th 2022

In T2D, a patient’s cardiovascular phenotype can help predict the pattern of future cardiovascular events (Clinical Research in Cardiology)

Categories: Cardiovascular, Genetics, News
Tags: GLP1 RA, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Genetics
Tags: GLP1 RA, SGLT2 inhibitors, Type 2 Diabetes

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently

March 30th 2022

Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes (Diabetes Therapy)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

March 26th 2022

Dapagliflozin contributes to the control of CV risk factors and reduces the risk of microvascular complications (nephropathy and retinopathy) and other non-classical complications of T2DM. The underuse of SGLT2i in general and dapagliflozin in particular, even in patients whose profiles suggest that they could greatly benefit from SGLT2i treatment, indicates that greater effort is needed to translate scientific evidence into actual clinical practice to improve patients’ quality of life (Diabetes Therapy )

Categories: Medication, News
Tags: dapagliflozin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, SGLT2 inhibitors, Type 2 Diabetes

Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function

March 25th 2022

Early intervention with SGLT2i may have renoprotective effects in T2D patients with rapid decline and preserved renal function (Journal of Diabetes Investigation)

Categories: Medication, Nephropathy, News
Tags: renoprotective, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: renoprotective, SGLT2 inhibitors, Type 2 Diabetes

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

March 21st 2022

The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care (Diabetes Therapy)

Categories: News, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience

March 6th 2022

Our real-world data on SGLT2i showed promising results in reductions in HbA1c, weight, and insulin requirements in type 1 diabetes. Benefits were more pronounced in individuals with higher baseline HbA1c and BMI. DKA remained a major concern, despite educational measures (Diabetes Care)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 1 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 1 Diabetes

Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis

February 17th 2022

SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Journal of Diabetes Research)

Categories: Medication, News
Tags: SGLT2 inhibitors, uric acid

Categories: Medication
Tags: SGLT2 inhibitors, uric acid

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes

February 2nd 2022

SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in primary prevention of MACCE and HF and GLP-1RA for HF. These data call for primary prevention trials using these agents and their combination (Diabetes Care)

Categories: Cardiovascular, Medication, News
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors

January 27th 2022

The ESC recently added SGLT2 inhibitors to the management guidelines for HFrEF following good outcomes from DAPA-HF [18] and EMPEROR-Reduced [19] over the last 2 years. We hope that further supporting evidence for SGLT2 inhibitors in the management of HFpEF follows with the results of the ongoing DELIVER trial expected soon, and that as a result similar changes to guidelines may be added to support the use of SGLT2 inhibitors in the management of HFpEF (Diabetes Therapy)

Categories: Cardiovascular, Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: heart failure, SGLT2 inhibitors

Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors

January 19th 2022

Our study demonstrated high rates of residual cardio-kidney outcomes and treatment failure in patients with DKD treated with SGLT2is. Patients with high baseline CV risk and the presence of certain conditions, such as atrial fibrillation, PVD, and heart failure, were at higher risk for cardio-kidney events (BMC Medicine)

Categories: Cardiovascular, Nephropathy, News, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Nephropathy, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Combined SGLT-2 and ACE inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial

January 5th 2022

A distinct RAS modulation by SGLT-2i occurs in diabetic kidney disease reflected by enhancement of the beneficial Angiotensin-(1–7) providing a molecular background for this renoprotective therapeutic approach (Diabetes, Obesity and Metabolism)

Categories: Medication, Nephropathy, News
Tags: ACE inhibition, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: ACE inhibition, SGLT2 inhibitors, Type 2 Diabetes

Network meta-analysis on the effects of SGLT2 inhibitors versus finerenone on cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease

December 31st 2021

Given the above limitations of this study, its findings may suggest that among patients with T2D and CKD SGLT2 inhibitors are more effective than finerenone in reducing renal and cardiovascular endpoints, especially renal and cardiac failure events(Frontiers in Pharmacology)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: CKD, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication, Nephropathy
Tags: CKD, SGLT2 inhibitors, Type 2 Diabetes

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

December 17th 2021

Therapy with SGLT-2 inhibitors in patients with cardiometabolic and renal diseases results in a sustained to moderate reduction of the composite CV death or hospitalization for HF, robust reduction of HF and renal outcomes, moderate reduction of CV mortality, total mortality and MACE (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication, Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 11
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskBoehringer IngelheimNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors elderly Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership